Opinion|Videos|October 21, 2024
Final Thoughts on Dravet Syndrome Management
Author(s)M. Scott Perry, MD
Key Takeaways
- Early diagnosis in Dravet syndrome is critical to prevent developmental delays and cognitive impairments, enhancing long-term outcomes.
- Achieving seizure freedom is a primary goal, utilizing antiepileptic drugs, dietary therapies, and novel treatments like cannabidiol and fenfluramine.
Scott Perry, MD, discusses how effective management of Dravet syndrome requires a multidisciplinary approach, emphasizing the critical importance of early diagnosis and aggressive treatment aimed at achieving seizure freedom, which can significantly improve long-term outcomes and quality of life for patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you provide any takeaway messages on the management of Dravet syndrome for your fellow HCPs?
- Please also touch on the importance of early diagnosis and seizure freedom.
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis
2
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
3
Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype
4
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
5